Conv. Plasma
Nigella Sativa
Peg.. Lambda

All antiandrogen studies
Meta analysis
Home COVID-19 treatment researchAntiandrogenAntiandrogens (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  

Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign”

Wambier et al., Journal of the American Academy of Dermatology, doi:10.1016/j.jaad.2020.05.079
May 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
Analysis of 175 patients hospitalized with severe COVID-19, showing androgenetic alopecia (AGA) in 42% of women and 79% of men. Authors hypothesize that COVID-19 severity is androgen-mediated, and recommend study of antiandrogen treatments.
Wambier et al., 21 May 2020, peer-reviewed, 14 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAntiandrogensAll
Abstract: 680 Research Letters Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The ‘‘Gabrin sign’’ To the Editor: Dr Frank Gabrin was the first American physician to die of severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection. Dr Gabrin suffered from androgenetic alopecia and was a long-term survivor of bilateral testicular cancer.1 The association between SARS-CoV-2 infectiveness and the androgen pathway has been previously described.2 Androgen-mediated SARS-CoV-2 J AM ACAD DERMATOL AUGUST 2020 vulnerability may help explain the disproportioned mortality rate among men.3 We present further epidemiologic evidence that androgen sensitivity might be associated with severe symptoms leading to hospitalization due to COVID-19. Previously, we reported a possible association between male patients hospitalized with COVID-19 and androgenetic alopecia (AGA); however, the study was limited by its population size of 41 men.4 In this communication, we present additional data from patients with confirmed COVID-19 admitted Fig 1. Epidemiologic characteristics of 175 individuals hospitalized due to severe symptoms of COVID-19 from March 23, 2020, to April 12, 2020. A, The study population had male-to-female ratio of 2.3:1. B, Androgenetic alopecia (AGA) was present in 42% of the women and in 79% of the men. C, Notably, the violin plots demonstrate there was an older age distribution in the women compared with the men. AGA severity was categorized by specific sex scales: HamiltoneNorwood scale (HNS) for men and Ludwig scale (LS) for women into groups: ‘‘no alopecia’’ for HNS ¼ 1 or LS ¼ 0; ‘‘moderate AGA’’ for HNS ¼ 2 or LS ¼ 1; or ‘‘severe AGA’’ for HNS [2 or LS [1. D, Although age was widely proportional among patients with no alopecia, moderate AGA, and severe AGA, there was a slight tendency for younger age in men with moderate AGA and in women with no alopecia compared with the respective severe AGA groups. The white circle represents the median, the bar in the center represents the interquartile range, and the thin lines represent the 95% confidence interval. The wider sections of the violin plot represent a higher probability that members of the population will take on the given value and the thinner sections represent a lower probability. J AM ACAD DERMATOL VOLUME 83, NUMBER 2 Research Letters 681 Fig 2. Possible targets of the androgen pathway for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prophylaxis and adjuvant therapy. Antiandrogen therapies include gonadotropin-releasing hormone (GnRH ) analogs (degarelix, goserelin, leuprolide, leuprorelin, nafarelin), which stop luteinizing hormone (LH ) secretion and induce chemical castration. Testosterone is regarded as the main androgen hormone, and its production is inhibited by ketoconazole, an inhibitor of steroidogenesis. Dutasteride and finasteride, 5- -reductase inhibitors, target synthesis of dihydrotestosterone, the most potent intrinsic androgen hormone. Androgen receptor inhibitors may be steroidal (abiraterone, cyproterone, nomegestrol, or spironolactone), or nonsteroidal (apalutamide, bicalutamide, darolutamide, enzalutamide, flutamide, or nilutamide). Transmembrane protease, serine 2 (TMPRSS2) blockers include bromhexine, camostat, and nafamostat. ACE, Angiotensin converting enzyme. due to severity criteria (mainly low peripheral oxygen saturation) to 3 tertiary hospitals in Madrid, Spain. The patients were randomly..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop